Munson Health
 
Preventive Cardiology: Statins

Back to Document

by Scholten A
IMAGE

Common Names

  • Lovastatin (Altoprev, Mevacor)
  • Simvastatin (Zocor)
  • Pravastatin (Pravachol)
  • Fluvastatin (Lescol)
  • Atorvastatin (Lipitor)
  • Rosuvastatin (Crestor)
 

Side Effects

 

Other Interactions

Statins can interact with certain foods, herbs, and supplements. Here are examples of potential interactions:
If you would like to take herbs or supplements while taking a statin, check with your doctor first.
 

Other Potential Concerns

If you have any of the following conditions, tell your doctor before you are prescribed statins:
  • Alcohol abuse
  • Liver disease
  • Organ transplant and take medicine to prevent transplant rejection
  • Recent major surgery
  • Pregnant or breastfeeding—Statins are not recommended in pregnant or nursing women.

Common Side Effects

More common side effects include:
  • Gas
  • Upset stomach
  • Abdominal pain
  • Diarrhea
  • Constipation
  • Headache
  • Flu-like symptoms
  • Fatigue
  • Muscle pain
  • Skin rash

Less Common Side Effects

Less common, but more serious side effects include:
  • Liver problems
  • Myopathy (muscle weakness)
  • Rhabdomyolysis
  • Kidney failure
  • Memory problems and confusion
  • Increased blood sugar levels
 

RESOURCES

American Heart Association
http://www.heart.org/

US Food and Drug Administration
http://www.fda.gov/

 

CANADIAN RESOURCES

Health Canada
http://www.hc-sc.gc.ca/index%5Fe.html/

Heart and Stroke Foundation of Canada
http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.2796497/k.BF8B/Home.htm

 

RESOURCES


Amarenco P, Bogousslavsky J, Callahan A III, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med . 2006;355:549-59.


Drug Therapy for Cholesterol. American Heart Association website. Available at: http://www.heart.org/HEARTORG/Conditions/Cholesterol/PreventionTreatmentofHighCholesterol/Drug-Therapy-for-Cholesterol%5FUCM%5F305632%5FArticle.jsp . Updated June 14, 2012. Accessed December 14, 2012.


Grundy SM, Cleeman JL, Merz CN et al. National Heart, Lung, and Blood Institute, American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines. Circulation . 2004;110:227-239.

Keeping cholesterol under control. US Food and Drug Administration website. Available at: http://www.fda.gov/ . Accessed on January 28, 2003.


Lemaitre RN, Psaty B, Heckbert SR, et al. Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults. Arch Intern Med . 2002;162:1395-1400.


Lipid-Lowering Pharmacotherapy Overview. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed/what.php. Updated July 3, 2012. Accessed December 14, 2012.


Middleton A, Binbrek AS, Fonseca FA, et al. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. Curr Med Res Opin . 2006;22: 1181-91.


Statins. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed/what.php. Updated November 24, 2010. Accessed December 9, 2010.


Statins. United States Food and Drug Administration website. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm294358.htm. Updated November 21, 2012. Accessed December 14, 2012.


Statin Drugs. EBSCO Natural and Alternative Treatments website. Available at: http://www.ebscohost.com/healthlibrary. Updated July 25, 2012. Accessed December 14, 2012.


Stender S, Schuster H, Barter P, et al. Comparison of rosuvastatin with atorvastatin, simvastatin, and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab. 2005;7:430-8.


Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fuorodeoxyglucose positron emission tomography. J Am Coll Cardiol . 2006;48:1825-31.


1/30/2009 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed/what.php : Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769-1781.


3/6/2012 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed/what.php: FDA announces safety changes in labeling for some cholesterol-lowering drugs. US Food and Drug Administration website. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm293623.htm. Published February 28, 2012. Accessed March 6, 2012.

 

Revision Information